SCHEMBL1310786

SCHEMBL1310786

Cc1c(N)cn[nH]c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658974 0.76
SCHEMBL5140170 0.76
SCHEMBL11704753 0.73
SCHEMBL8544011 0.73
SCHEMBL12065687 0.73
SCHEMBL11709325 0.71 ALDH1A1 (0.41)
SCHEMBL6155854 0.70
SCHEMBL13906524 0.70 ALDH1A1 (0.49)
SCHEMBL25342148 0.68 ALDH1A1 (0.39)
SCHEMBL25342190 0.68 ALDH1A1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154139-A1 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D. E. SHAW RESEARCH, LLC 2025-05-15 US disclosed
EP-4472624-A2 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D.E. Shaw Research, LLC (US) 2024-12-11 EP disclosed
CN-118973564-A Pyridazinone compounds as TRPA1 inhibitors D·E·萧尔研究有限责任公司 2024-11-15 CN disclosed
WO-2023185073-A1 PARP7 INHIBITOR AND USE THEREOF 诺沃斯达药业(上海)有限公司 2023-10-05 WO disclosed
WO-2023150591-A2 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed
WO-2023150591-A2 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed
US-8455495-B2 Pyridazino-pyridinone compounds and methods of use AMGEN INC. (US) 2013-06-04 US disclosed
US-8420649-B2 Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof AMGEN INC. (US) 2013-04-16 US disclosed
EP-2334674-B1 Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. AMGEN INC (US) 2012-06-06 EP disclosed
US-20110281864-A1 Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof AMGEN INC. (US) 2011-11-17 US disclosed
US-20110275629-A1 Pyridazino-pyridinone Compounds and Methods of Use AMGEN INC. (US) 2011-11-10 US disclosed
EP-2334674-A1 PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. Amgen, Inc (US) 2011-06-22 EP disclosed
EP-2334673-A1 PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF Amgen Inc. (US) 2011-06-22 EP disclosed
WO-2010025201-A1 PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. AMGEN INC. (US) 2010-03-04 WO disclosed
WO-2010025202-A1 PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF AMGEN INC. (US) 2010-03-04 WO disclosed